Trial Profile
A phase I study of STI 571 [imatinib mesylate] in PH+ [Philadelphia chromosome-positive] leukaemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 25 Sep 2005 New trial record.